The pressor responses to oral and intravenous tyramine were not different from controls in migrainous patients with or without a history of attacks triggered by foods. However, patients who reported a dietary trigger were more likely to develop headache after tyramine administration than those without such a dietary history. Pressor responses to intravenous tyramine in patients with cluster headache were indistinguishable from controls. A group of five males with platelet monoamine oxidase activity one standard deviation or more below that of male controls required less intravenous tyramine to raise blood pressure by 30 mm Hg than males with monoamine oxidase levels within one standard deviation of the controls. This finding suggests that platelet monoamine oxidase activity to some extent reflects that of total body monoamine oxidase A plus B.
Tyramine, which is present in many foodstuffs, may provoke a hypertensive response (the "cheese effect") in patients taking monoamine oxidaseinhibiting drugs. ' 2 A superficial similarity between the list of foods contraindicated in this group and those believed by some migrainous patients to initiate their migraine attacks led Hanington3 to postulate that tyramine might similarly be a cause of dietary migraine. Hanington34 also suggested that a deficiency of monoamine oxidase might account for the susceptibility of some migraine patients to tyramine-containing foods. In man the only peripheral source of this enzyme readily available for clinical study is the platelet, which contains solely the B form.5 Sandler et al. 6 first reported a transitory deficiency of monoamine oxidase B during a migraine attack, which received subsequent confirmation.78 In addition, lower values have been demonstrated in certain patients between attacks9-" although careful analysis of a large series points to the phenomenon being limited to male patients."
The mean and range of platelet monoamine oxidase activity, however, in patients believing dietary factors to initiate their attacks are no different from values in those who do not. 8'101 Particularly low activity has been indentified in patients with cluster headache9 " who seldom ascribe their attacks to dietary factors other than alcoholic beverages.
Tyramine is an indirectly acting pressor agent have claimed that migrainous subjects are more sensitive to its intravenous administration than control subjects. Oral tyramine does not appear to have been studied in this context. If platelet monoamine oxidase reflects enzyme activity elsewhere in the body, measurements in this tissue might thus provide some index of ability to inactivate tyramine.
The studies reported here were designed to test the pressor response of affected subjects to oral and intravenous tyramine in relation both to platelet monoamine oxidase activity and to history of dietary provocation. 828 in 37 male subjects with cluster headache" (Littlewood J, Glover V, Sandler M, Petty R, Peatfield R and Rose FC, in preparation). These patients were subdivided into those with and without a history of dietary provocation of their headache. From the migrainous group, some patients were selected with activity values at least one standard deviation (SD) below the normal mean for their sex. As platelet monoamine oxidase activity and dietary history were not significantly related, a 2 x 2 factorial design could be used. Intravenous tyramine tests were performed on 21 patients and oral studies on 14 of them; intravenous tests were also carried out on six controls drawn from departmental staff, five of whom also received oral tyramine. In addition, intravenous tests were performed in three patients with cluster headache in an active phase (without prior monoamine oxidase measurement) and in six with quiescent cluster headache, five of whom had low platelet activity. Written consent was obtained from all patients and the project was approved by the Charing Cross Hospital Ethical Committee. All subjects discontinued any prophylactic medication at least 24 h before the tests and fasted overnight before the oral tests. There were no significant ECG abnormalities in any of the patients. Platelets were prepared for monoamine oxidase assay"' on the same day as the intravenous pressor test and the result expressed as number of standard deviations from the normal mean for the subject's sex. The patients were telephoned at home 24 to 48 h after each test and asked about any subsequent development of headache.
Intravenous tests
The protocol was based on that of Ghose et al. "6 The patients rested recumbent and a blood sample was taken for platelet monoamine oxidase determination. The intravenous cannula was left in situ, and kept patent with 0 9% saline solution. Blood pressure was measured with a Bard medical automatic sphygomomanometer which provides a digital readout of pulse, and systolic and diastolic blood pressures. After initial stabilisation, a bolus injection of tyramine was given; readings were then made every 30 to 40 s, continuing through the rise and fall until the pressure started to rise again, whereupon the next dose was given. Doses of 0.5, 1, 2 and 4 and sometimes 8 mg were
given at approximately 5 min intervals until the blood pressure rise exceeded 20 mm Hg. For analysis, the mean of the rise and subsequent fall after each dose was recorded. A best fit dose response curve was prepared from the pressor effects of 1, 2 and 4 and, when available, 8 mg of tyramine and the result expressed as dosage (mg/kg body weight) needed to raise the systolic blood pressure by 30 mm Hg.
Oral tyramine
The experimental protocol was modified from that of Elsworth et al. " Capsules containing 25 mg and 200 mg of tyramine were prepared, and fasting patients were given 100 mg and 200 mg in separate doses, 30 to 40 min apart. Pulse and blood pressure were recorded every 5 min, the latter by manual external sphygmomanometry. Again The only significant result was obtained when the small group of males with low monoamine oxidase activity (more than one SD below the mean for male controls) was compared with the 15 other males tested. The former needed significantly less intravenous tyramine (p < 0-05; two-tailed Student's t test) to produce a 30 mm Hg rise in blood pressure. When the two males with active cluster headache were excluded from the 15, the difference between the two groups became even more significant (p < 0-02). The male with common migraine with the lowest monoamine oxidase activity (2-2 nmoles tyramine oxidized/30 min/mg protein compared with the mean for male controls of needed 47-4 ,ug/kg of intravenous tyramine, compared with mean of 76-8 Ag/kg required by the controls. There was only one female with activity less than one SD below that of female controls. Her pl-atelet monoamine oxidase activity was 9 nmoles tyramine oxidized/30 min/mg protein and she needed 86 Ag of tyramine/kg to raise blood pressure by 30 mm Hg.
The patients' subsequent headaches are tabulated in table 2. It will be seen that more of the dietary patients did develop headaches; the time of onset was highly variable, though the earlier headaches were significantly more severe (p < 0-01 -Spearman Rank Correlation test). Two of the six control subjects developed trivial headaches but none of the cluster headache patients experienced any pain whatsoever. Intensity of subsequent headache in migrainous patients was not related to actual rise in Pressor sensitivity to tyramine in patients with headache 
